COL18A1 and lung carcinoma: We subsequently compared ProAgio side-by-side with several other agents that are known to have effects on HUVEC cells, such as Avastin, Endostar (an endostatin derivative approved for lung cancer treatment in China), LM609 and Cilengitide, using HUVEC cells.